Securities code: 688180 Securities abbreviation: Junshi Biosciences Announcement No.: Pro 2025-004

Shanghai Junshi Biomedical Technology Co., Ltd

2024 Annual Results Forecast

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

1. Forecast of performance for the current period

(1) The performance forecast period

January 1, 2024 to December 31, 2024.

(2) Performance forecast

1. According to the preliminary calculation of the financial department, it is expected that the annual operating income in 2024 will be 194,900.00 yuan

Right, compared with the same period of the previous year, an increase of about 446.4501 million yuan, a year-on-year increase of about 29.71%.

2. It is estimated that the annual R&D expenses in 2024 will be about 127,400.00 yuan, a decrease compared with the same period last year

about 663.4695 million yuan, a year-on-year decrease of about 34.24%.

3. It is estimated that the net profit attributable to the owners of the parent company in 2024 will be -129,200.00 yuan

Right, compared with the same period last year, the loss decreased by about 991.4319 million yuan, a year-on-year decrease of about 43.42%.

4. It is estimated that the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses in 2024 will be about 1273000000 yuan, a decrease of about 1024588000 yuan compared with the same period of the previous year, and a year-on-year decrease of about 44.59%.

(3) The performance forecast has not been audited by a certified public accountant.

Second, the performance of the same period last year

(1) In 2023, the company will achieve an operating income of 150,254.99 million yuan.

(2) R&D expenses in 2023 will be 1937.4695 million yuan.

(3) The total profit of the company in 2023 will be -2491.6946 million yuan, the net profit attributable to the owners of the parent company will be -2283.4319 million yuan, and the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses will be -2297.5588 million yuan.

(4) The company's basic earnings per share in 2023 will be -2.32 yuan.

3. The main reasons for the change in the performance of the current period

(1) During the reporting period, the company's operating income increased, mainly due to the increase in sales revenue of commercial drugs compared with the same period last year. As of the end of the reporting period, the company had toripalimab injection (trade name: Tuoyi?) ), adalimumab injection (trade name: Junmaikang?) ), deuterium hydrobromide deuterium remidevir tablets (trade name: Mindwei? ) and ongoresimab injection (trade name: Junshida?) Four commercialized drugs. Thanks to the improvement of the sales efficiency of the company's commercialization team, the increase in the number of approved indications for toripalimab and the indications included in the national medical insurance catalog, the sales of the company's core product toripalimab in the domestic market increased significantly year-on-year during the reporting period.

As of the disclosure date of this announcement, toripalimab has been approved for marketing in the United States, the European Union, India, the United Kingdom, Jordan, Australia and other countries and regions, and the marketing authorization application in Singapore has been accepted. The Company and its partners will actively promote the marketing application and commercialization process of toripalimab in the cooperative regions, and actively explore the possibility of more indications being marketed in some regions.

With the improvement of the accessibility of approved products and indications after they are included in the National Medical Insurance Catalogue, the successive approval of more products and indications for marketing in the future, and the continuous commercialization expansion of the global market, the company's commercial competitiveness will continue to be improved.

(2) The company's net profit attributable to the owners of the parent company in 2024 is still in the red, but the amount of loss is reduced compared with the same period of the previous year, mainly because the company actively implements the action plan of "improving quality and efficiency and emphasizing returns", continuously strengthens various cost control, reduces unit production costs, improves sales efficiency, and focuses resources on more potential R&D projects. During the reporting period, the company's R&D expenses are expected to be about 127,400.00 yuan, a decrease of about 34.24% compared with the same period last year. The company has maintained the efficient advancement of its core pipeline while controlling R&D expenses, and has made a number of progresses. During the Reporting Period, the NDA for the first-line treatment of advanced triple-negative breast cancer, the first-line treatment of advanced renal cell carcinoma and the first-line treatment of extensive-stage small cell lung cancer was approved by the National Medical Products Administration (NMPA), and the NDA for the first-line treatment of melanoma and bevacizumab for the first-line treatment of advanced hepatocellular carcinoma was accepted by the NMPA. Ongoliximab injection was approved for marketing by the State Food and Drug Administration. The company is accelerating the R&D and marketing application of late-stage pipelines such as anti-tumor anti-BTLA monoclonal antibody tifcemalimab (code: TAB004/JS004) and anti-IL-17A monoclonal antibody (code: JS005), and continues to explore PD-1/VEGF bispecificity

The early-stage pipeline, including sexual antibody (code: JS207), Claudin18.2 ADC drug (code: JS107), PI3K-α oral small molecule inhibitor (code: JS105), CD20/CD3 bispecific antibody (code: JS203), anti-DKK1 monoclonal antibody (code: JS015) and other products, will promote more advantageous products and indications to enter the registration clinical trial stage as soon as possible.

4. Risk Warning

The company does not have any major uncertainties that affect the accuracy of the content of this earnings forecast.

5. Other explanatory matters

The above forecast data is only preliminary accounting data, and the specific and accurate financial data are subject to the audited 2024 annual report officially disclosed by the company.

The announcement is hereby made.

Shanghai Junshi Biomedical Technology Co., Ltd

board of directors

January 18, 2025